(CercleFinance.com) – Merck today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Ervebo, now indicated for the prevention of disease caused by Ebola virus from Zaire in from the age of 1 year.
The vaccine was previously approved for use in people 18 years of age and older.
Merck states that Ervebo does not protect against other Ebolavirus or Marburgvirus species and its duration of protection is unknown.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
